Cardiff Oncology (CRDF) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company developing novel cancer therapies targeting PLK1 inhibition, with lead candidate onvansertib in oral form for multiple cancer indications including RAS-mutated metastatic colorectal cancer (mCRC), metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC).

• Focuses on combination therapies with standard-of-care agents, leveraging tumor genomics and biomarker assays to refine patient response assessment.

• Multiple ongoing and planned clinical trials, including a pivotal Phase 2 trial (CRDF-004) in first-line RAS-mutated mCRC and investigator-initiated studies in other cancers.

Financial performance and metrics

• As of May 5, 2025, 66,525,854 shares of common stock were issued and outstanding; authorized to issue up to 150,000,000 shares of common stock and 20,000,000 shares of preferred stock.

• Net tangible book value as of March 31, 2025, was $70.9 million ($1.07 per share); after the offering, as adjusted net tangible book value would be $216.3 million ($1.77 per share), with immediate dilution of $0.91 per share to new investors at an assumed offering price of $2.68 per share.

Use of proceeds and capital allocation

• Net proceeds intended for general corporate purposes, including product development and commercialization, R&D, administrative expenses, license or technology acquisitions, working capital, and capital expenditures.

• Management retains broad discretion over allocation; may also use proceeds for potential acquisitions or investments, though no current commitments exist.